摘要
目的探讨与分析尤瑞克林治疗穿支动脉病变型脑梗死的近期及远期临床疗效。方法采用随机1:1平行对照的方法,将60例穿支动脉型脑梗死患者随机分为尤瑞克林组和对照组,每组各30例。疗程14d,随访3m。治疗组给予尤瑞克林及常规治疗,对照组仅给予常规治疗。于治疗前及治疗后14d、3m,按照美国国立卫生院卒中量表(NIHSS)对两组患者进行神经功能缺损程度评定并用Barthel指数(BI)评分评定日常生活能力,比较两组的临床疗效。结果与治疗前相比,治疗后14d、3m两组NIHSS评分均下降,但尤瑞克林组优于对照组(P<0.05),且临床疗效显著,总有效率、显效率显著高于对照组。两组在治疗后3m BI评分较14d时均有所改善,但尤瑞克林组改善更明显(P<0.05)。结论尤瑞克林可明显改善穿支动脉型脑梗死急性期的神经功能缺损,并改善远期预后。
Objective To observe and evaluate the short and long term therapeutic effects of urinary kallidinogenase’s treatment on acute penetrating arterial cerebral infarction.Methods Sixty patients with acute penetrating arterial cerebal infarction were enrolled and randomly divided into treating group（n = 30） and control group（n = 30）.The course of treatment is 14 days,follow-up period is 3 months.All the cases were treated with conventiona1 neurologic therapy and cases in the treatment group were additionally treated with urinary ka1lidinogenase.National institutes of health stroke scale（NIHSS） and the Barthel index of activities of daily living（ADL） were assessed before and 14d after the treatment and the clinical effects were also recorded and compared.The Barthel index of ADL score were assessed and compared 14d after the treatment and 3 months after outbreak.Result After 14days and 3 months,NIHSS of both UK and control groups were decreased as compared with the pretreatment,the decrease of NIHSS in UK group was more significant than that in control group（P 0.05）.The total improvement rate and total response rate of UK group significantly increased than that of control group.After 3 months,BI of both UK and control group were increased as compared with 14d after the treatment.The increase of BI in UK group was more significant than that in control group（P 0.05） 。Conclusion Urinary kallidinogenase can obviously improve neurologic impairment in acute stage and prognosis in long-term of acute penetrating arterial cerebral infarction.
出处
《中风与神经疾病杂志》
CAS
CSCD
北大核心
2013年第7期609-611,共3页
Journal of Apoplexy and Nervous Diseases
关键词
尤瑞克林
穿支动脉病变
脑梗死
近期疗效
远期预后
Urinary kallidinogenase
Penetrating arterial disease
Cerebral infarction
Shot-term effect of treatment
Long-term prognosis.
